Montreal, Canada, December 6, 2001 – ProMetic Life Sciences Inc. (TSE: PLI), a leading biopharmaceutical company in Canada, announced the expansion of it Research and Development team yesterday at a special session at the Biotech Research Institute of Montreal. The appointments announced were: Dr. Chris Penney, as Director of R&D, Therapeutic Program, Dr. Boulos Zacharie, Director of Chemistry, and Dr. Lyne Gagnon, Director of Biology.
Dr. Chris Penney comes to ProMetic from BioChem Pharma where he held the position of Group Leader He brings with him 20 years of industrial experience in immunology and medicinal chemistry. At ProMetic, he will lead the Therapeutic Program and a team of 20 scientists.
Dr. Zacharie, also of BioChem Pharma, participated in the synthesis of two drugs that are presently in the market: 3TC and 1amivudine. Dr. Lyne Gagnon has acquired extensive experience in inflammation and immunotoxicity during her postdoctoral studies at Harvard Medical School and at BioChem Pharma.
“We are delighted to have this strong scientific team join us at such a pivotal time in our company’s development,” said Pierre Laurin, CEO of ProMetic. “This expansion is part of a natural progression of our core technologies into high value therapeutic applications.”
The new members acknowledged their excitement about joining the ProMetic. “We are pleased to join a company that has established an internationally recognized expertise in bioseparation and is now looking to build on this core competency to develop a strong drug discovery and development program, said Dr. Penney.”
During the meeting, ProMetic gave a progress report on its lead compounds: PBI-1402 (cancer), PBI-1101 (inflammation), Alpha 1-antitrypsin (inflammation). The report indicated that the three compounds were well characterized, each with an excellent safety profile. They are expected to enter the clinic in early 2002.
ProMetic Life Sciences Inc. (TSE: PLI) has headquarters in Montreal, Quebec, additional facilities in the UK and a Development and Marketing team in USA. ProMetic owns proprietary enabling technology essential for use in therapeutics, large-scale drug purification, chemical genomics and proteomics, drug delivery and drug development. This existing technology can dramatically lower costs, increase yield, and improve efficacy of existing and new bio-pharmaceutical products. ProMetic accomplishes this through strategic partnerships and in-house therapeutic development.
This press release contains forward-looking statements that involve risks and uncertainties, including, but not limited to the Company’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products and to obtain contracts for its products and services and commercial acceptance of advanced affinity separation technology. Shareholders are cautioned that these statements are predictions and these actual events or results may differ materially from those anticipated in these forward-looking statements.
Contacts: ProMetic Worldwide